A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (Mermaid-1)

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Capable of giving signed informed consent, which includes a mandatory genetic informed consent and compliance with the requirements and restrictions listed in the informed consent forms (ICFs) and study protocol
• Age ≥18 years at the time of screening
• Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage II-III) disease
• Complete resection of the primary NSCLC

• Postoperative imaging demonstrating unequivocal evidence of disease recurrence or tissue biopsy-proven disease recurrence
• EGFR-mutant and/or ALK-translocation
• Mixed small cell and NSCLC histology
• Received any prior adjuvant therapy for NSCLC or any prior exposure to durvalumab

To learn more, visit ClinicalTrials.Gov

Study Type

Phase III

Principal Investigator(s)

Vikas Dembla, MD

Sponsor(s)

AstraZeneca